United States

SHERIDAN, WYOMING - April 4, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

WASHINGTON, 4 March 2026: AdvaMed said the U.S. Senate has approved legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, and the association called on the House of Representatives to move quickly on passage. The medtech trade group said the vote matters because authorization for the two programs lapsed on 30 September 2025, leaving early-stage medical technology companies without the certainty they need as they pursue product research and development.

SHERIDAN, WYOMING - March 31, 2026 - Early-stage medtech companies could regain a key non-dilutive funding route in 2026 after the Senate passed legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, reducing uncertainty that has persisted since the programs' authorization lapsed on September 30, 2025. AdvaMed said the Senate action restores momentum for grants that support early research and development at startups and small manufacturers, and it urged the House of Representatives to move quickly on passage. The association framed the programs as an important bridge for companies that struggle to finance next-generation device development before products reach patients or later-stage commercial milestones.

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

SHERIDAN, WYOMING - December 30, 2025 - CPGIO says it has expanded its digital retail footprint by launching on multiple major marketplaces, positioning the company to support consumer brands with broader omnichannel distribution across a mix of mass, specialty, and B2B wholesale platforms.

Multi-marketplace expansion and timing

The company reported successful launches across Nordstrom, Chewy, Lowe's, Faire, and Best Buy, with the rollout beginning in November 2025. For consumer brands, the announcement signals a continued push toward diversified third-party marketplace presence as a growth lever, particularly as retailers extend marketplace models beyond core categories. For service providers and operators, the business impact typically centers on onboarding speed, catalog and content compliance, inventory synchronization, and the ability to manage pricing and pack-out strategy consistently across channels.

SHERIDAN, WYOMING - December 30, 2025 - Public Service Enterprise Group (PSEG) says New York State's comptroller has granted final approval for an extension of PSEG Long Island's operations services agreement with the Long Island Power Authority (LIPA), locking in continued grid-operations responsibilities through the end of 2030.

Contract extension now fully cleared

PSEG said the LIPA Board of Trustees awarded PSEG Long Island a five-year extension of the existing contract on September 25, followed by approval from the New York State attorney general in October and final approval from the comptroller this week. The extension begins January 1, 2026, and runs through December 31, 2030. PSEG Long Island has operated the electric grid on behalf of LIPA since 2014, covering Long Island and the Rockaways.

SHERIDAN, WYOMING - December 27, 2025 - United Airlines has rolled out a new set of mobile app capabilities designed to reduce airport friction, improve real-time transparency, and shift more travel support into self-service workflows during peak travel demand.

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber has expanded its presence in the electric vehicle supply chain as Nissan chooses the AVID GT as original equipment for the new Nissan LEAF in the United States, underlining the growing role of EV-optimized tire technology in improving range, comfort and safety for mainstream electric cars.

EV-Optimized Tires for a Core Mass-Market Electric Vehicle

Yokohama Rubber has begun supplying its AVID GT in size 215/55R18 95H as factory equipment for the latest Nissan LEAF EV launched in the U.S. market in 2025. Positioned as a key electric model for drivers transitioning from internal combustion engines to battery-electric vehicles, the new LEAF benefits from a tire package specifically engineered to support higher curb weights, instant torque and demanding efficiency targets.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.